1212-57-3

Upstream product

• 2969-81-5 Ethyl 4-bromobutyrate 
• 100-46-9 benzylamine 
• 5959-36-4 ethyl 4-aminobutyrate 

Downstream Products

• 74798-54-2 ethyl 4-aminobutirrate 
• 1400993-69-2 C₁₃H₁₈N₂O₄S 
• 1400994-02-6 C₂₂H₃₇N₃O₅S 
• 1400993-68-1 C₁₃H₁₈N₄O₄S 
• 154195-33-2 1-benzyl-5-bromo-3-chloro-azepan-2,4-dione 
• 154195-29-6 1-benzyl 3-chloro-azepan-2,4-dione 
• 154195-31-0 1-benzyl-4-bromo-azepan-2,5-dione 
• 154195-30-9 1-benzyl-azepan-2,5-dione 
• 154195-26-3 ethyl-4-(N-benzyl-N-chloroacetylamino) butanoate 

Relevant academic research and scientific papers

RAPID DEBENZYLATION OF N-BENZYLAMINO DERIVATIVES TO AMINO-DERIVATIVES USING AMMONIUM FORMATE AS CATALYTIC HYDROGEN TRANSFER AGENT

Various N-benzyl derivatives of amino acids and amines were deprotected to the corresponding free amino acids and amines using ammonium formate as the hydrogen source.

CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO

CRF receptor antagonists are disclosed which may have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in mammals, such as stroke. The CRF receptor antagonists of this invention have the following structure (a) including pharmaceutically acceptable salts, esters, solvates, stereoisomers, and prodrugs thereof, wherein R1, R2, R3, Y, Ar, and Het are as defined herein. Compositions containing a CRF receptor antagonist and a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.